Carlo Gambacorti‐Passerini

1986–2025 年に発表

別表記
Carlo Gambacorti Passerini
124
論文数
23,252
被引用数
77
h 指数
120
i10 指数

被引用数

Carlo Gambacorti‐Passerini の年別被引用数1979 年: 被引用 5 件1988 年: 被引用 1 件1989 年: 被引用 1 件1990 年: 被引用 1 件1992 年: 被引用 1 件1993 年: 被引用 3 件1994 年: 被引用 3 件1995 年: 被引用 8 件1996 年: 被引用 10 件1997 年: 被引用 10 件1998 年: 被引用 25 件1999 年: 被引用 44 件2000 年: 被引用 59 件2001 年: 被引用 91 件2002 年: 被引用 168 件2003 年: 被引用 204 件2004 年: 被引用 130 件2005 年: 被引用 108 件2006 年: 被引用 109 件2007 年: 被引用 115 件2008 年: 被引用 120 件2009 年: 被引用 124 件2010 年: 被引用 121 件2011 年: 被引用 123 件2012 年: 被引用 173 件2013 年: 被引用 188 件2014 年: 被引用 220 件2015 年: 被引用 221 件2016 年: 被引用 267 件2017 年: 被引用 190 件2018 年: 被引用 157 件2019 年: 被引用 572 件2020 年: 被引用 702 件2021 年: 被引用 784 件2022 年: 被引用 557 件2023 年: 被引用 379 件2024 年: 被引用 679 件2025 年: 被引用 244 件2026 年: 被引用 10 件1980〜1987 年は被引用が無いため表示していません1991 年は被引用が無いため表示していません

引用元

国・地域

この著者を引用した国・地域の世界地図アメリカ合衆国: 引用元論文 2,416 件、この内訳の 25.7%イタリア: 引用元論文 784 件、この内訳の 8.3%ドイツ: 引用元論文 644 件、この内訳の 6.8%イギリス: 引用元論文 636 件、この内訳の 6.8%中国: 引用元論文 578 件、この内訳の 6.1%フランス: 引用元論文 487 件、この内訳の 5.2%カナダ: 引用元論文 286 件、この内訳の 3%スペイン: 引用元論文 284 件、この内訳の 3%オーストラリア: 引用元論文 268 件、この内訳の 2.9%日本: 引用元論文 259 件、この内訳の 2.8%スイス: 引用元論文 248 件、この内訳の 2.6%オランダ: 引用元論文 208 件、この内訳の 2.2%
0%25.7%その他 24.6%

分野

  • Medicine66.1%
  • Biochemistry, Genetics and Molecular Biology28.7%
  • Immunology and Microbiology2.4%
  • Computer Science0.6%
  • Chemistry0.4%
  • Pharmacology, Toxicology and Pharmaceutics0.3%
  • その他1.5%

トピック

  • Chronic Myeloid Leukemia Treatments10.3%
  • Acute Myeloid Leukemia Research7.8%
  • Chronic Lymphocytic Leukemia Research6%
  • Eosinophilic Disorders and Syndromes4.4%
  • Myeloproliferative Neoplasms: Diagnosis and Treatment3.1%
  • Acute Lymphoblastic Leukemia research2.6%
  • その他65.8%

共著者

全論文

検索で開く
  1. Clinical and biological implications of driver mutations in myelodysplastic syndromes

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Anthony R. Green, Jacqueline Boultwood, Paresh Vyas, Eva Hellström‐Lindberg, David Bowen, Mario Cazzola, Michael R. Stratton, Peter J. Campbell - Blood 2013 被引用: 1,832

  2. A Phase 2 Trial of Ponatinib in Philadelphia Chromosome–Positive Leukemias

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2013 被引用: 1,124

  3. Ponatinib efficacy and safety in Philadelphia chromosome–positive leukemia: final 5-year results of the phase 2 PACE trial

    著者: , , , , , , , , , , , , , , , , , , , , , , , , - Blood 2018 被引用: 583

  4. SomaticSF3B1Mutation in Myelodysplasia with Ring Sideroblasts

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , E. Joanna Baxter, J Score, Anna Gallì, Matteo Giovanni Della Porta, Erica Travaglino, Michael J. Groves, Sudhir Tauro, Nikhil C. Munshi, Kristina Anderson, Adel K. El‐Naggar, Andrej Fischer, Ville Mustonen, Alan J. Warren, Nicholas C.P. Cross, Anthony R. Green, P. Andrew Futreal, Michael R. Stratton, Peter J. Campbell - New England Journal of Medicine 2011 被引用: 1,216

  5. Bosutinib Versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia: Results From the Randomized BFORE Trial

    著者: , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2017 被引用: 493

  6. Integrative pathway enrichment analysis of multivariate omics data

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Dale W. Garsed, Mark Gerstein, Gad Getz, Abel González-Pérez, Qianyun Guo, Marta Gut, David Haan, Mark Hamilton, Nicholas J. Haradhvala, Arif Harmanci, Mohamed Helmy, Carl Herrmann, Julian M. Hess, Asger Hobolth, Ermin Hodzic, Chen Hong, Henrik Hornshøj, Keren Isaev, José M. G. Izarzugaza, Rory Johnson, Todd A. Johnson, Malene Juul, Randi Istrup Juul, Andre Kahles, Abdullah Kahraman, Manolis Kellis, Ekta Khurana, Jaegil Kim, Jong K. Kim, Young-Wook Kim, Jan Komorowski, Jan O. Korbel, Sushant Kumar, Andrés Lanzós, Michael S. Lawrence, Shantao Li, Kjong-Van Lehmann, Shantao Li, Xiaotong Li, Ziao Lin, Eric Minwei Liu, Lucas Lochovsky, Shaoke Lou, Tobias Madsen, Kathleen Marchal, Iñigo Martincorena, Alexander Martinez‐Fundichely, Yosef E. Maruvka, Patrick D. McGillivray, William Meyerson, Ferran Muiños, Loris Mularoni, Hidewaki Nakagawa, Morten Muhlig Nielsen, Keunchil Park, Kiejung Park, Jakob Skou Pedersen, Oriol Pich, Tirso Pons, Sergio Pulido-Tamayo, Benjamin J. Raphael, Iker Reyes-Salazar, Matthew A. Reyna, Esther Rheinbay, Mark A. Rubin, Carlota Rubio-Pérez, Radhakrishnan Sabarinathan, S. Cenk Şahinalp, Gordon Saksena, Leonidas Salichos ほか 1,360 名 - Nature Communications 2020 被引用: 236

  7. Phase 3 trial of gilteritinib plus azacitidine vs azacitidine for newly diagnosed FLT3mut+ AML ineligible for intensive chemotherapy

    著者: , , , , , , , , , , , , , , , , , , , , - Blood 2022 被引用: 126

  8. Bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia: final results from the BFORE trial

    著者: , , , , , , , , , , , , , , , , , , , - Leukemia 2022 被引用: 141

  9. Ponatinib vs Imatinib in Frontline Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia

    著者: , , , , , , , , , , , , , , , , , , , , - JAMA 2024 被引用: 114

  10. Dasatinib and low-intensity chemotherapy in elderly patients with Philadelphia chromosome–positive ALL

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Josep‐María Ribera, Renato Bassan, Marc Delord, Dieter Hoelzer, Hervé Dombret, Oliver G. Ottmann - Blood 2016 被引用: 326

  11. Selective cytotoxicity of betulinic acid on tumor cell lines, but not on normal cells

    著者: , , , , , , - Cancer Letters 2002 被引用: 530

  12. Long-term safety review of tyrosine kinase inhibitors in chronic myeloid leukemia - What to look for when treatment-free remission is not an option

    著者: , , , , , - Blood Reviews 2022 被引用: 64

  13. Cancer LncRNA Census reveals evidence for deep functional conservation of long noncoding RNAs in tumorigenesis

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Mark Gerstein, Gad Getz, Abel González-Pérez, Qianyun Guo, Marta Gut, David Haan, Mark P. Hamilton, Nicholas J. Haradhvala, Arif Harmanci, Mohamed Helmy, Carl Herrmann, Julian M. Hess, Asger Hobolth, Ermin Hodzic, Chen Hong, Henrik Hornshøj, Keren Isaev, José M. G. Izarzugaza, Rory Johnson, Todd A. Johnson, Malene Juul, Randi Istrup Juul, André Kahles, Abdullah Kahraman, Manolis Kellis, Ekta Khurana, Jaegil Kim, Jong K. Kim, Young-Wook Kim, Jan Komorowski, Jan O. Korbel, Sushant Kumar, Andrés Lanzós, Erik G. Larsson, Michael S. Lawrence, Dong-Hoon Lee, Kjong-Van Lehmann, Shantao Li, Xiaotong Li, Ziao Lin, Eric Minwei Liu, Lucas Lochovsky, Shaoke Lou, Tobias Madsen, Kathleen Marchal, Iñigo Martincorena, Alexander Martinez‐Fundichely, Yosef E. Maruvka, Patrick D. McGillivray, William Meyerson, Ferran Muiños, Loris Mularoni, Hidewaki Nakagawa, Morten Muhlig Nielsen, Marta Paczkowska, Keunchil Park, Kiejung Park, Jakob Skou Pedersen, Oriol Pich, Tirso Pons, Sergio Pulido-Tamayo, Benjamin J. Raphael, Jüri Reimand, Iker Reyes-Salazar, Matthew A. Reyna, Esther Rheinbay, Mark A. Rubin, Carlota Rubio-Pérez, Radhakrishnan Sabarinathan, S. Cenk Sahinalp ほか 1,362 名 - Communications Biology 2020 被引用: 190

  14. Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Patrizia Tosi, Francesco Lanza, Massimo Massaia, Mauro Turrini, Felicetto Ferrara, Carmela Gurrieri, Daniele Vallisa, Maurizio Martelli, Enrico Derenzini, Attilio Guarini, Annarita Conconi, Annarosa Cuccaro, Laura Cudillo, Domenico Russo, Fabrizio Ciambelli, Anna Maria Scattolin, Mario Luppi, Carmine Selleri, Elettra Ortu La Barbera, Celestino Ferrandina, Nicola Di Renzo, Attilio Olivieri, Monica Bocchia, Massimo Gentile, Francesco Marchesi, Pellegrino Musto, Augusto B. Federici, Anna Candoni, Adriano Venditti, Carmen Fava, Antonio Pinto, Piero Galieni, Luigi Rigacci, Daniele Armiento, Fabrizio Pane, Margherita Oberti, Patrizia Zappasodi, Carlo Visco, Matteo Franchi, Paolo Grossi, Lorenza Bertù, Giovanni Corrao, Livio Pagano, Paolo Corradini - The Lancet Haematology 2020 被引用: 554

  15. SETBP1 induces transcription of a network of development genes by acting as an epigenetic hub

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , - Nature Communications 2018 被引用: 157

  16. Bosutinib for pretreated patients with chronic phase chronic myeloid leukemia: primary results of the phase 4 BYOND study

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Kevin R. Kelly, P. Le Coutre, Carmen Martínez Chamorro, Vivian G. Oehler, G. Orti Pascual, Andreas Petzer, Ester Pungolino, Giovanna Rege‐Cambrin, Françoise Rigal‐Huguet, Gail J. Roboz, P. Rousselot, Fermín Sánchez‐Guijo, Guillermo Sanz Santillana, Philippe Schafhausen, C. Scheid, Stefan Schmidt, Giorgina Specchia, Juan Luis Steegmann, Leif Stenke - Leukemia 2020 被引用: 83

  17. Hematologic and Cytogenetic Responses to Imatinib Mesylate in Chronic Myelogenous Leukemia

    著者: , , , , , , , , , , , - New England Journal of Medicine 2002 被引用: 2,030

  18. Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome–positive chronic myeloid leukemia patients with resistance or intolerance to imatinib

    著者: , , , , , , , , , , , , , , - Blood 2011 被引用: 461

  19. Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure

    著者: , , , , , , , , , , , - Blood 2012 被引用: 318

  20. Bosutinib Versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia: Results From the BELA Trial

    著者: , , , , , , , , , , - Journal of Clinical Oncology 2012 被引用: 469

  21. Pathway and network analysis of more than 2500 whole cancer genomes

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Keith A. Boroevich, John Busanovich, Peter J. Campbell, Joana Carlevaro-Fita, Dimple Chakravarty, Calvin Wing Yiu Chan, Ken Chen, Jung Kyoon Choi, Jordi Deu-Pons, Klev Diamanti, Lars Feuerbach, J. Lynn Fink, Nuno A. Fonseca, Joan Frigola, Carlo Gambacorti‐Passerini, Dale W. Garsed, Mark Gerstein, Qianyun Guo, Marta Gut, Mark P. Hamilton, Nicholas J. Haradhvala, Arif Harmanci, Mohamed Helmy, Carl Herrmann, Julian M. Hess, Asger Hobolth, Ermin Hodzic, Chen Hong, Henrik Hornshøj, Keren Isaev, Rory Johnson, Todd A. Johnson, Malene Juul, Randi Istrup Juul, André Kahles, Manolis Kellis, Jaegil Kim, Jong K. Kim, Youngwook Kim, Jan Komorowski, Jan O. Korbel, Sushant Kumar, Andrés Lanzós, Erik Larsson, Donghoon Lee, Kjong-Van Lehmann, Shantao Li, Xiaotong Li, Ziao Lin, Eric Minwei Liu, Lucas Lochovsky, Shaoke Lou, Tobias Madsen, Iñigo Martincorena, Alexander Martinez‐Fundichely, Yosef E. Maruvka, Patrick D. McGillivray, William Meyerson, Ferran Muiños, Loris Mularoni, Hidewaki Nakagawa, Morten Muhlig Nielsen, Keunchil Park, Kiejung Park, Tirso Pons, Iker Reyes-Salazar, Esther Rheinbay, Carlota Rubio-Pérez, Gordon Saksena, Leonidas Salichos ほか 1,354 名 - Nature Communications 2020 被引用: 115

  22. Tyrosine phosphatases regulate resistance to ALK inhibitors in ALK+ anaplastic large cell lymphoma

    著者: , , , , , , , , , , , , , , , , , , , - Blood 2021 被引用: 49

  23. Long‐term effects of crizotinib in ALK‐positive tumors (excluding NSCLC): A phase 1b open‐label study

    著者: , , , , , , , , , , , , , , , , , - American Journal of Hematology 2018 被引用: 110

  24. Evaluating the performance of large language models in haematopoietic stem cell transplantation decision‐making

    著者: , , , , , , , , , , , , , , - British Journal of Haematology 2023 被引用: 16